PT - JOURNAL ARTICLE AU - Teresa H. Praetorius AU - Vivian Lac AU - Basile Tessier-Cloutier AU - Janine Senz AU - Tayyebeh M. Nazeran AU - Martin Köbel AU - Marcel Grube AU - Bernhard Krämer AU - Paul J. Yong AU - Stefan Kommoss AU - Michael S. Anglesio TI - Is endometriosis metastasizing? Shared somatic alterations suggest common origins across endometriotic lesions AID - 10.1101/2021.04.12.21255355 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.12.21255355 4099 - http://medrxiv.org/content/early/2021/04/19/2021.04.12.21255355.1.short 4100 - http://medrxiv.org/content/early/2021/04/19/2021.04.12.21255355.1.full AB - Endometriosis has yielded controversy on whether it constitutes a single disease or distinct types. Current classification systems poorly correlate with the severity of symptoms and do not provide prognostic tools that can guide management or predict recurrence or success of treatment. Our previous work has uncovered recurrent cancer-driver alterations in endometriosis. Here we examined anatomically separate types of endometriosis (ovarian endometriomas, deep infiltrating, and superficial endometriosis) in 27 individual patients for evidence of a common origin. Specimens were analyzed using high-sensitivity targeted sequencing with orthogonal validation from droplet digital PCR and mutation-surrogate immunohistochemistry. Results show clonality between lesions is common (observed in 9/27 cases) and that endometriomas have potential for higher mutational load, often resulting in multiple subclonal lineages. Our data further confirms that endometriosis is generally an oligoclonal disease with dissemination likely to consist of multiple epithelial clones travelling together.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMajor funding was provided by Canadian Institutes of Health Research (Early Career Investigator Grant in in Maternal, Reproductive, Child & Youth Health to M.S. Anglesio) M. Koebel received support through the Calgary Laboratory Services research support fund (RS19-609). M.S. Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program (managed by the BC Cancer Foundation). This project received technical and data management support from Calgary Laboratory Services and the Genetic Pathology Evaluation Centre (GPEC). GPEC receive core support from BC's Gynecological Cancer Research team (OVCARE), and the VGH+UBC Hospital Foundation. Dr. M Koebel was supported by internal research support (RS19-621). Funders did not have input on research design, collection of data, interpretation of results, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Tuebingen University Hospital Research Ethics Board approved collection and use of the materials. The University of British Columbia research ethics board approved the use of specimen in research. The project was conducted in compliance with the Canadian Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans (TCPS2, 2018), effort to obtain written informed consent was exercised for all patients. Specimen from non-contactable patients (lost contact/deceased) treated more than 5 years before the start of the study were included under institutionally approved waiver of consent (Tuebingen University Hospital Research Ethics Board). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is contained within the manuscript and or associated supplemental information.